Meeting Banner
Abstract #1126

Novel Fluorine-18 Labeled Fe3O4@Al(OH)3 Nanoparticles as Dual Contrast Agents for Simultaneous PET/MRI

Sarah Belderbos1,2, Manuel Antonio González-Gómez3, Yolanda Piñeiro3, Frederik Cleeren2,4, Jens Wouters1,2, Bella B. Manshian2,5, Stefaan J. Soenen2,5, Christophe M. Deroose2,6, Willy Gsell1,2, Guy Bormans2,4, Jose Rivas3, and Uwe Himmelreich1,2

1Biomedical MRI, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium, 2MoSAIC, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium, 3NANOMAG Group, Department of Applied Physics, Research Technological Institute, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, 4Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 5Nanohealth and Optical Imaging Group, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium, 6Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium

The emergence of (pre)clinical PET/MRI scanners is accompanied by the development of novel contrast agents. Aluminum hydroxide magnetic nanoparticles (Fe3O4@Al(OH)3 NPs) can overcome limitations of iron oxide NPs after labeling with Na18F, allowing visualization with PET (high sensitivity, low background) and MRI (high resolution, longitudinal NP follow-up). In this study, labeling of novel Fe3O4@Al(OH)3 nanostructures with Na18F was rapid. In vivo, radiolabeled NPs accumulated in liver of healthy mice, while cells labeled with radiolabeled NPs were also seen in lungs. Our results indicate the potential of these novel nanostructures for cell tracking with high sensitivity, specificity and resolution using PET/MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract Presentation Video